BioSpace News Archive

The California Speech Language Hearing Association (CSHA) is thrilled to announce its implementation of comprehensive brand and communications strategies designed to build on CSHA’s 53-year record of serving its members and the people who need them, and to tell the stories of their life-changing work.

Moog Inc. (NYSE: MOG.A and MOG.B) announced today that a notice of redemption is being issued to the holders of the Company’s 5.25% senior notes due in 2022 (the “Notes”), to redeem and retire all of the outstanding Notes.

Access-Power, Inc., (“ACCR or the Company”), a Grand Haven based medical marijuana clone corporation is pleased to announce that we have completed our 2018 year-end audit, review of bank records/expenses, and final submission of our 2018 US Business Tax Return with our MASTER TAX ADVISOR.

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures.

Dune Medical Devices, (Alpharetta, GA), a medical device company focused on improving the effectiveness and outcome of cancer therapy through real-time tissue characterization, is presenting cutting-edge data and an expanded technology platform during the 2019 San Antonio Breast Cancer Symposium (SABCS) December 10-14.

“Regulatory authorization of the Tandem Control-IQ algorithm for use as part of a hybrid closed-loop system is a huge win for the type 1 diabetes (T1D) community and a critical step forward in making day-to-day life better for people living with the disease.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of the t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid-closed loop feature designed to help increase time in range (70-180 mg/dL)1, and the first system cleared to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency,

The U.S. Food and Drug Administration today cleared for marketing in the U.S. the first fully disposable duodenoscope.

Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system, today announced the award of a competitive Congressionally Directed Medical Research Program (CDMRP) contract.